Based on the current evidence, advanced practitioners could offer brentuximab vedotin to patients with CD30-positive HL or ALCL, as it may offer the potential for long-term remission, particularly in those with refractory disease or post–ASCT. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.